Educació en competències: TFG-Farmàcia
Ros Simó, Enric; Vázquez Cruz, Santiago
Abstract
Metabolic syndrome is a pathology that has exponentially increased its worldwide prevalence in the last few
decades. However, its treatment is still not optimal, hence there is a big necessity to find better therapies.
Soluble Epoxide Hydrolase, an enzyme involved in the arachidonic acid cascade, has recently arisen as one
of the potential targets to treat metabolic syndrome. It is believed that the selective inhibition of this enzyme
could lead to positive effects in several disorders that conform the disease. Many compounds have
been synthetized and tested, several of them presenting a high inhibitory potency. Nevertheless, none has yet
reached the market due to their poor pharmacokinetic profiles. Over the years, many strategies have been
followed to overcome this issue. In this dissertation, the enzyme structure and function, the physiologic role
of its metabolic substrates, and the design of the different classes of inhibitors are reviewed.
Keywords: metabolic syndrome, soluble Epoxide Hydrolase, lead optimisation, pharmacokinetic profile.
Reception date: 28/09/2016
Acceptance date: 21/10/2016